Important Securities Fraud Class Action Update for Pacira BioSciences Investors with Losses Over $100K

Investor Alert: Pacira BioSciences Securities Fraud Class Action

If you invested in Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023, and August 8, 2024, you may have experienced significant financial losses exceeding $100,000. The Rosen Law Firm, renowned for its global investor advocacy, is currently inviting these investors to consider leading a securities fraud class action lawsuit against the company. With a deadline set for March 14, 2025, now is the time to act.

Class Action Dates and Details

The Rosen Law Firm has set a crucial date: those wishing to serve as lead plaintiffs must file their applications by March 14, 2025. A lead plaintiff is essential as they represent the class members in court and guide the litigation process.

Investors participating in this class action will not incur out-of-pocket costs, thanks to a contingency fee arrangement. This means you can seek compensation for your losses without upfront legal fees.

How to Join the Class Action

If you're interested in joining the lawsuit, view the submission link here, or you can reach out directly to Phillip Kim, Esq. via phone at 866-767-3653 or via email at pkim@rosenlegal.com for further information.

Background of the Lawsuit

The lawsuit alleges that statements made by Pacira during the class period were misleading, relating to their patents on the drug Exparel. According to the lawsuit, the company falsely represented its patent protections while knowing their strength was already challenged in litigation. Notably, rulings made in favor of eVenus regarding these patent claims reveal weaknesses in Pacira's assertions.

Investors were led to believe that the earnings potential of Exparel would accelerate, which significantly contributed to its stock value. However, as the reality of the tenuous patent situation became known, investor trust eroded, leading to substantial financial losses.

Why Choose Rosen Law Firm?

The Rosen Law Firm boasts extensive experience in securities class actions, having secured record settlements against companies. Named as a top firm for multiple years, Rosen Law Firm has recovered hundreds of millions for investors globally. In 2019 alone, they secured over $438 million. By choosing Rosen Law Firm, investors engage with a seasoned team that prioritizes accountability and results.

The firm continues to emphasize the importance of having competent and experienced legal counsel when participating in class actions. Many firms merely serve as intermediaries or lack a direct litigation background, which can impact the outcome and recovery potential for investors.

No Class Certified Yet

It's vital to remember that the class for this specific action has not yet been certified. Until that happens, investors are encouraged to seek their counsel if they wish to be part of this movement, or they may choose to remain absent and see how the case unfolds. Participating as a lead plaintiff may enhance your opportunity for recovery, but is not a requirement for sharing in any future settlements.

Stay Updated

Rosen Law Firm frequently updates investors through their social media channels: follow them on LinkedIn, Twitter, and Facebook.

This is a pivotal moment for investors who may have faced financial losses due to misleading representations by Pacira. Act now to ensure your voice is heard and your rights are protected in this significant legal battle.